(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 September 2021 (10.09.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/178902 A1

(51) International Patent Classification:
A61P 11/00 (2006.01) *A61P 31/12* (2006.01)
A61P 11/16 (2006.01)

(21) International Application Number:
PCT/US2021/021217

(22) International Filing Date:
05 March 2021 (05.03.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/986,566	06 March 2020 (06.03.2020)	US
63/008,540	10 April 2020 (10.04.2020)	US
63/015,299	24 April 2020 (24.04.2020)	US
63/054,298	21 July 2020 (21.07.2020)	US
63/062,843	07 August 2020 (07.08.2020)	US
63/104,229	22 October 2020 (22.10.2020)	US
63/105,637	26 October 2020 (26.10.2020)	US
63/140,591	22 January 2021 (22.01.2021)	US

(71) Applicant: **OMEROS CORPORATION** [US/US]; 201 Elliott Avenue West, Seattle, WA 98119 (US).

(72) Inventors: **DEMOPULOS, Gregory, A.**; 201 Elliott Avenue West, Seattle, WA 98119 (US). **QUINTON, Tineka, J.**; 201 Elliott Avenue West, Seattle, WA 98119 (US). **WHITAKER, John, Steven**; 201 Elliott Avenue West, Seattle, WA 98119 (US).

(74) Agent: **QUINTON, Tineka, J.**; Omeros Corporation, 201 Elliott Avenue West, Seattle, WA 98119 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

(54) Title: METHODS OF INHIBITING MASP-2 FOR THE TREATMENT AND/OR PREVENTION OF CORONAVIRUS-INDUCED ACUTE RESPIRATORY DISTRESS SYNDROME




FIG. 52A

(57) Abstract: In one aspect, the invention provides methods for treating, inhibiting, alleviating, or preventing acute respiratory distress syndrome, pneumonia, or some other pulmonary or other manifestation of coronavirus infection, such as thrombosis, in a mammalian subject infected with coronavirus, such as SARS-CoV-2. The methods comprise the step of administering to a subject infected with coronavirus an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In one embodiment, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody, or fragment thereof that specifically binds to a portion of SEQ ID NO:6. In one embodiment, the MASP-2 inhibitory agent is a small molecule MASP-2 inhibitory compound. In one embodiment, the subject is a human subject suffering from COVID- 19-induced acute respiratory distress syndrome (ARDS) and requires supple-

WO 2021/178902 A1

[Continued on next page]

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

— *with sequence listing part of description (Rule 5.2(a))*

mental oxygen prior to treatment and the MASP-2 inhibitory agent is administered in an amount sufficient to discontinue the need for supplemental oxygen.